Agios Pharm Stock In The News

AGIO Stock  USD 32.42  0.60  1.89%   
Our overall analysis of Agios Pharm's news coverage and content from conventional and social sources shows investors' bearish mood towards Agios Pharm. The specific impact of Agios Pharm news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Agios Pharm's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Agios Pharm headlines in addition to utilizing other, more conventional financial analysis modules. Check out Agios Pharm Backtesting and Agios Pharm Hype Analysis.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Agios Pharm Today Top News and Investor Outlook

Yahoo News
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
https://finance.yahoo.com/news/agios-webcast-conference-call-third-110000222.html
 Neutral
Yahoo News
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
https://finance.yahoo.com/news/options-traders-know-something-agios-143400413.html
 Bullish
Yahoo News
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
https://finance.yahoo.com/news/agios-pharmaceuticals-agio-appreciated-positive-115648825.html
 Bullish
Yahoo News
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
https://finance.yahoo.com/news/companies-agios-pharmaceuticals-nasdaq-agio-122857065.html
 Neutral
Yahoo News
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
https://finance.yahoo.com/news/fda-grants-orphan-drug-tag-153300796.html
 Bullish
Yahoo News
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
https://finance.yahoo.com/news/agios-announces-fda-orphan-drug-110000033.html
 Bullish
Yahoo News
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
https://finance.yahoo.com/news/why-zimmer-zbh-down-3-153116720.html
 Bullish
Yahoo News
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
https://finance.yahoo.com/news/agios-present-2024-cantor-global-110000491.html
 Neutral
Yahoo News
Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?
https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-street-115023464.html
 Bullish
Yahoo News
Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?
https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-good-112326556.html
 Bullish

Agios Pharm Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Agios and other traded companies coverage with news coverage. We help investors stay connected with Agios headlines for the 18th of January 2025 to make an informed investment decision based on correlating the impacts of news items on Agios Stock performance. Please note that trading solely based on the Agios Pharm hype is not for everyone as timely availability and quick action are needed to avoid losses.
Agios Pharm's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Agios Pharm investors visualize upcoming and past events in order to time the market based on Agios Pharm noise-free hype analysis.
Agios Pharm stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Agios earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. That information is available publicly through Agios media outlets and privately through word of mouth or via Agios internal channels. However, regardless of the origin, that massive amount of Agios data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.

Agios Largest EPS Surprises

Earnings surprises can significantly impact Agios Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-03-06
2013-12-31-0.34-0.4-0.0617 
2014-08-07
2014-06-30-0.4-0.54-0.1435 
2019-08-01
2019-06-30-1.7-1.87-0.1710 
2017-02-16
2016-12-31-1.51-1.340.1711 
2016-05-05
2016-03-31-0.79-0.610.1822 
2015-02-17
2014-12-31-0.58-0.76-0.1831 
View All Earnings Estimates

Agios Pharm Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Agios Pharm Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
news
16th of January 2025
January 17, Feast Day of Agios Antonios O Megas
at greekcitytimes.com 
Gurufocus Stories at Macroaxis
13th of January 2025
Agios Pharmaceuticals Inc Announces Key Milestones and Strategic Plans for 2025
at gurufocus.com 
news
10th of January 2025
Agios Pharmaceuticals, Inc. Receives Average Recommendation of Moderate Buy from Brokerage...
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
8th of January 2025
FDA Accepts Agios Supplemental New Drug Application for PYRUKYN
at gurufocus.com 
Yahoo News
18th of December 2024
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of A...
at finance.yahoo.com 
Macroaxis News
11th of December 2024
Disposition of 200 shares by Scadden David of Agios Pharm at 46.28 subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
19th of November 2024
Disposition of 300 shares by Foster-cheek Kaye I of Agios Pharm at 32.21 subject to Rule 1...
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
31st of October 2024
Agios Pharmaceuticals Inc Q3 2024 Earnings EPS Surpasses Estimates, Revenue at 9.0 Million
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Agios Pharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Agios Pharm's short interest history, or implied volatility extrapolated from Agios Pharm options trading.
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Agios Pharm Backtesting and Agios Pharm Hype Analysis.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.88
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.